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Abstract
Since December 2019, the clinical symptoms of coronavirus disease 2019 (COVID-19) and its
complications are evolving. As the number of COVID patients requiring positive pressure ven-
tilation is increasing, so is the incidence of subcutaneous emphysema (SE). We report 10
patients of COVID-19, with SE and pneumomediastinum. The mean age of the patients
was 59 ± 8 years (range, 23–75). Majority of them were men (80%), and common symptoms
were dyspnoea (100%), fever (80%) and cough (80%). None of them had any underlying lung
disorder. All patients had acute respiratory distress syndrome on admission, with a median
PaO2/FiO2 ratio of 122.5. Eight out of ten patients had spontaneous pneumomediastinum
on their initial chest x-ray in the emergency department. The median duration of assisted ven-
tilation before the development of SE was 5.5 days (interquartile range, 5–10 days). The high-
est positive end-expiratory pressure (PEEP) was 10 cmH2O for patients recieving invasive
mechanical ventilation, while 8 cmH2O was the average PEEP in patients who had developed
subcutaneous emphysema on non-invasive ventilation. All patients received corticosteroids
while six also received tocilizumab, and seven received convalescent plasma therapy, respect-
ively. Seven patients died during their hospital stay. All patients either survivor or non-sur-
vivor had prolonged hospital stay with an average of 14 days (range 8−25 days). Our
findings suggest that it is lung damage secondary to inflammatory response due to
COVID-19 triggered by the use of positive pressure ventilation which resulted in this compli-
cation. We conclude that the development of spontaneous pneumomediastinum and SE
whenever present, is associated with poor outcome in critically ill COVID-19 ARDS patients.
Introduction
In December 2019, a novel respiratory virus that originated from Wuhan (China), later
named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was found to
be the cause of disease called coronavirus disease 2019 (COVID-19). It was recognised as
a substantial global public health emergency and SARS-CoV-2 was declared a pandemic
on March 11, 2020 [1].
Hypoxaemic respiratory failure leading to acute respiratory distress syndrome (ARDS) is
the most frequent complication of COVID-19 [2]. Positive pressure ventilation (PPV) both
invasive and non-invasive has proven itself as life-saving rescue treatment for COVID-19
ARDS. PPV use though also has its demerits, with around 1−2% of patients developing baro-
trauma while recieving it [3]. It occurs due to either increased intra-alveolar pressure, high
tidal volume or intrinsic positive end-expiratory pressure (PEEPi), leading to dynamic hyper-
inflation and is more frequently observed with invasive ventilation compared to non-invasive
ventilation [4]. However, in our institute, we observed subcutaneous emphysema (SE) and
pneumomediastinum in COVID-19 patients without any exposure to invasive mechanical ven-
tilation, suggesting an alternate pathology.
We identified 10 patients with COVID-19 in our institute who had developed SE and pneu-
momediastinum while recieving PPV. Nine of them were receiving non-invasive ventilation
and one was on invasive ventilation at the time of the event.
We therefore conducted this case series to determine the predisposing factors leading to SE
and pneumomediastinum in patients with ARDS associated with COVID-19 disease.
Methods
Study setting and duration
Ten patients with COVID-19 who were admitted in the intensive care unit (ICU) of the Aga
Khan University Hospital (AKUH), Karachi, Pakistan, from April 2020 till June 2020 were
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included in the study. The AKUH is a 650-bed, JCIA-certified,
tertiary care university hospital, which was the first hospital in
the country to admit COVID-19 patients.
Study definition
SE and pneumomediastinum occur when air is infiltrated into
subcutaneous layers of skin. The extravasation of air to other
areas like mediastinum, peritoneum and pleural cavity, is called
pneumomediastinum, pneumoperitoneum and pneumothorax,
respectively.
Acute respiratory distress syndrome (ARDS): ARDS is an acute
diffuse, inflammatory lung injury, leading to increased pulmonary
vascular permeability, increased lung weight and loss of aerated
lung tissue. It is characterized by hypoxaemia and bilateral radio-
graphic opacities and is associated with increased venous admix-
ture, increased physiological dead space and decreased lung
compliance.
As per Berlin’s criteria [5], ‘ARDS is defined on basis of bilat-
eral lung opacities appearing within 1 week of clinical insult or
new respiratory symptoms, not explained by effusions, collapse
or nodules or cardiac failure and fluid overload and having
PaO2/FiO2 ratio less than 300 on a PEEP of < or = 5’.
Cytokine release syndrome (CRS): is a specific form of inflam-
matory reaction due to the release of pro-inflammatory cytokines,
like interleukin-6, in response to infection, certain medicines
(chemotherapeutic agent) and other factors. It is graded from 1
to 4 in terms of severity. In the presence of symptoms like
fever, nausea, fatigue, headache which are not life threatening, it
is graded as 1. In the presence of fluid responsive hypotension
or hypotension requiring low-dose vasopressor or oxygen require-
ment of <40%, it is graded as 2. If oxygen requirement is greater
than or equal to 40% or hypotension requires higher dose of vaso-
pressor it is graded as 3 and in the presence of life-threatening
features or ventilatory support it is graded as 4 [6]).
Inclusion criteria
Patients were included on the basis of laboratory confirmed
diagnosis of COVID-19 based on their positive reverse
transcriptase-polymerase chain reaction (RT-PCR) assay and
chest x-ray (CXR) findings suggestive of SE or pneumothorax
or pneumomediastinum.
Study design and methodology
This is a retrospective review of clinical data of COVID-19
patients who developed ARDS and then subsequently developed
pneumomediastinum and SE. A designed Performa was filled,
which recorded demographic data, clinical symptoms, radio-
logical findings, oxygenation status and ventilator requirement
and the treatment received, hospital and ICU length of stay and
mortality. Duration of positive pressure ventilation and level of
positive end expiratory pressure (PEEP), along with cytokine
release syndrome grading (CRS grade) at the time of development
of SE and pneumomediastinum was recorded.
Imaging characteristics
Chest radiology consisted of a standard anteroposterior view.
Chest computed tomography (chest CT) was reviewed whenever
available. All chest x-ray images were reviewed by a senior con-
sultant radiologist, with greater than 10 years’ experience along
with their fellow/resident.
The chest radiographs were examined carefully for the pres-
ence of pneumomediastinum, SE and pneumothorax. They were
also analysed for severity score based on lung opacities at the
time of admission and on the day of development of pneumome-
diastinum or SE. A six-point scoring system was used for objective
measurement of lung opacities based on lung zones [7]. Both
lungs were divided into the upper, middle and lower zones, and
one point was given for opacity in each zone for a maximum
score of six.
Statistical analysis
SPSS Version 23 was used for data analysis. Descriptive statistics
was used to summarise the data, and the results were shown in
median and interquartile range or mean and standard deviation,
as appropriate. Categorical variables were summarised, as counts
and percentages.
Results
We identified 10 patients with COVID-19 from April till June
2020 who met our inclusion criteria. All the patients were treated
in ICU although one was not intubated. Three of the patients were
admitted directly to the ICU from emergency department (ED)
and others were shifted from high dependency unit (HDU) of
the hospital. Their demographics and baseline clinical character-
istics are shown in Table 1. The mean (±S.D.) age of the patients
Table 1. Demographics and baseline patient characteristics
Characteristics Patient (n = 10)








Ischaemic heart disease 2 (20%)
Malignancy 1 (10%)
Mean SOFA score on arrival 2.8 ± 1.0
(Range) (2–5)




Sore throat 3 (30%)
Bodyache 1 (10%)
Vitals on admission mean ± S.D. (range)
Systolic blood pressure – mmHg 131.3 ± 19.5 (100–160)
Diastolic blood pressure – mmHg 77.9 ± 8.8 (64–90)
Heart rate – beats per min 106.4 ± 19.0 (88–140)
Respiratory rate – per min 36.9 ± 17.5 (22–80)
Oxygen saturation – % 81.1 ± 12.6 (50–95)
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was 59 (±8) years (range 46–75) and 80% were men. The most
common presenting symptom was dyspnoea which was present
in all of the patients followed by fever (80%) and cough (80%).
The duration of symptoms from the onset until hospital admis-
sion was 9.2 days (range 2–20 days). Hypertension was the
most common comorbid condition found in six out of 10 patients
(60%), followed by diabetes seen in five patients (50%), ischaemic
heart disease in three (30%), and one patient (10%) had B-cell
lymphoma. The Charlson’s comorbidity index ranged from 0 to 4.
The average of CXR’s lung severity scoring was 3.5 out of 6 on
admission and 4.35 out of 6, at the time of development of SE.
This signifies involvement of greater than 2/3 of lung parenchyma
at the time of event (Table 2).
At the time of admission all the patients were in hypoxic
respiratory failure and their mean PaO2/FiO2 (P/F) ratio was
122.5 (range 106–145). Two of them had moderate ARDS while
P/F ratio of eight was consistent with severe ARDS based on
Berlins’ criteria. All patients required positive pressure ventilation
(PPV), either non-invasive ventilation (NIV) or invasive mechan-
ical ventilation (IMV) since their arrival in the ED.
The chest x-ray of eight patients (refer to Table 3) showed
spontaneous pneumomediastinum (SPM) at the time of their
ED arrival (Fig. 1).
The other two patients developed it after 1 day of ED stay.
With the progression of time, all of the patients developed SE
after days 1–4 of developing SPM. One patient developed it
after day 14 of SPM. Five of the patients also developed pneu-
mothoraces. One patient’s CXR showed SE and pneumothorax
developing on the same day (Fig. 2).
All others develop it after 3–10 days of developing SE. Three
patients also had an extension of air into peritoneum as seen by
their abdominal x-ray (AXR) and computerised tomography
(CT) scan (Fig. 3).
The median duration of assisted ventilation before SE ranged
from 1 to 9 days (average 5.5 days). Seven of the patients
developed it while recieving NIV and three were on invasive
mechanical ventilation at the time of SE. The average PEEP at
that time, for those on NIV was 8 cmH2O (range: 8–16
cmH2O) and for those on invasive ventilator was 10 cmH2O
(range: 8–12 cmH2O). Five patients had chest tube insertion
and others were managed conservatively. All patients required
endotracheal intubation except for one who was managed ini-
tially on non-invasive ventilation and then face mask. Invasive
mechanical ventilation was required either on the same day or
second day of development of SE. The average length of ICU
stay was 8.6 days (range 3–14 days).
At the time of development of SE, all patients were found
to have CRS. Eight patients were in CRS grade 3. Two were in
CRS grade 4 and both of them expired. The median ferritin
level for the group was 2354.5 ng/ml (interquartile range,
1156−4427), the median lactate dehydrogenase (LDH) level
was 868.5 IU/l (interquartile range, 767.5−1188.7), and the
median C-reactive protein (CRP) level was 229 mg/l (interquar-
tile range, 116.7−345.5). Creatinine phosphokinase (CPK) level
of only one patient was checked which was 2632 IU/l (normal
range: 46–171 IU/l).
All patients in our study received steroids, and five patients
received a combination of tocilizumab and convalescent plasma
along with steroids. The only two survivors in our case series
received this combination therapy. Seven patients (70%) received
tocilizumab either with plasma or with steroids and six patients
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CXR on day of S.E.
development
1 Y N D3 D3 Y Y D4 D10 MODS 3.5 4
2 Y N D4 N N N D4 D20 MODS 3.5 4.0
3 N N D1 PM, D2 SE N N N D2 D9 MODS 6 6
4 Y N D1 D2 Y Y D6 D14 MODS 2.5 3
5 N N D1 PM, D2 SE D8 Y N D7 D14 Septic
shock
3 4.5
6 Y N D4 SE DIO Y N D2 D14 Tension
PTX
5 5
7 Y N D2 N N N D2 Sent home Sent
home
4 4
8 Y N D1 PM, D3 PM, SE D3 Y Y D11 LAMA LAMA 4 4
9 Y N D14 N N N N Sent home Sent
home
4/6 4/6
10 Y N D1 SE N N N D6 D20 GI bleed 2.5 5
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dysfunction syndrome (MODS) and septic shock and one,
developed lower GI bleed after successful extubation and com-
plete resolution of SE. The two survivors had conservative man-
agement of their pneumomediastinum without chest tube
insertion, although they received combination treatment with
steroids, tocilizumab and convalescent plasma. One of the sur-
vivor was never intubated and was managed only on NIV. All
patients in our case series, both survivors and non-survivors
had a prolonged hospital stay with an average of 14 days
(range 8−25 days).
Discussion
This is the first case series on clinical characteristics and outcomes
of SE and pneumomediastinum in COVID-19 patients with
ARDS from Pakistan. Pneumomediastinum and SE usually occurs
after rupture of an over distended alveolus with air leaking into
surrounding mediastinum and along cervical fascial planes into
subcutaneous tissue. It can lead to pneumothorax, which is
defined as the presence of air between parietal and visceral pleura
causing difficulty with oxygenation [4]. The causes of pneumo-
mediastinum, SE and pneumothorax can be spontaneous or
traumatic.
It can also be a complication of positive pressure ventilation.
We have observed increased frequency of these complications in
COVID-19 ARDS patients compared to ARDS due to other
causes. Our patients were mostly male with mean age of 59,
which is the age group (50–70) associated with most critical
course of COVID-19 in our country [8, 9]. Diabetes and hyper-
tension were the most common comorbid conditions, which coin-
cides with COVID-19 dataset generated by the CDC from the 13
US states [10]. None of our patients were smokers or had any
underlying chronic lung condition prior to the illness.
As all of the patients in our case series were on positive pres-
sure ventilation at the time of the development of SE, barotrauma
can be hypothesised as a cause of this complication. Seven of our
patients were on non-invasive ventilation and three were on inva-
sive mechanical ventilation. Barotrauma manifesting as pneumo-
mediastinum, SE and/or pneumothorax is a known complication
of positive pressure ventilation. It is usually a form of ventilator-
induced lung injury (VILI) occurring due to increased stress and
pressure in alveoli. The susceptibility of lungs to develop VILI is
non-homogenous with some regions more at risk of barotrauma
than others. Dependent part of the lung can be damaged by
shear forces required for cyclical alveolar collapse and reopening
during expiration and inspiration with insufficient PEEP.
Similarly, non-dependent parts of the lung are more susceptible
to rupture with high inspiratory pressure of tidal volume. This
complication is though more reported with invasive ventilation
than non-invasive ventilation. Low tidal volume and low plateau
pressure strategy is therefore in practice in managing ARDS
patients on invasive mechanical ventilation to protect lung from
this complication [11]. Seventy per cent of our patients though
were on NIV including BIPAP and CPAP, at the time of develop-
ment of SE (Tables 4 and 5).
Despite frequent use of NIV for acute respiratory failure due to
varied causes, SE is very seldom reported with its use in literature
[12, 13] before COVID-19. It is therefore postulated that
COVID-19 patients with extensive lung damage might have
increased respiratory drive with persistent strong spontaneous
inspiratory efforts causing self-inflicted lung injury as postulated
by Gattinoni [14]. End expiratory pressure provided by NIV
increases the pressure gradient between alveoli and interstitium.
This pressure gradient might have over distended, already
damaged alveoli causing their rupture with further extension of
air into mediastinum and the pleura and subcutaneous tissue.
Fig. 3. Abdominal x-ray showing extensive pneumoperitoneum.
Table 4. Laboratory and radiological investigations
Laboratory data Patient (n = 10)
On admission: median (IQR)
White cell counts – × 109/l 9.05 (5.5–13.6)
Platelets – × 109/l 261.5 (183–357)
Serum creatinine – mg/dl 1.1 (0.7–1.7)
Total bilirubin – mg/dl 0.7 (0.4–0.9)
Infective Markers: median (IQR)
Highest ferritin – ng/ml 2354.5 (1156–4427)
Highest LDH – IU/l 868.5 (767.5–1188.7)
Highest CRP – mg/l 229 (116.7–345.5)
Highest procalcitonin – ng/ml 0.57 (0.36–6.29)
Highest D-dimer – mg/l FEU 5.35 (1.8–13.4)
pH: median (IQR)
On admission 7.43 (7.35–7.47)
Before pneumomediastinum 7.42 (7.40–7.51)
pO2: median (IQR)
On admission 71.7 (57.7–80.2)
Before pneumomediastinum 59.5 (51.9–65)
pO2/FiO2 ratio: median (IQR)
On admission 122.5 (106–145)
Before pneumomediastinum 71.5 (53–97)
Imaging: n (%)
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Another important finding to support this hypothesis is that at
time of development of SE, all of the patients, were either in grade 3
or grade 4 CRS, signifying severe inflammation process (Table 2).
Radiologically extensive lung involvement was also seen in
these patients’s CXR. CXR’s lung severity score averaged 3.5 out
of 6 on admission and 4.35 out of 6, at time of development of
SE, signifying involvement of greater than 2/3rd of lung paren-
chyma. This further supports our postulation that in COVID-19
ARDS, severe lung damage with concomitant rise in intra-alveolar
pressure might be a cause of spontaneous rupture of these hyper-
inflated alveoli with dissection of air along the bronchovesicular
sheath into mediastinum, pleural cavity and subcutaneous tissues
(Macklin effect). This progressive development of pulmonary
interstitial emphysema (PIE) has been experienced in a variety
of other viral pneumonias and also in patients with severe under-
lying lung disorder which affects alveoli (like ARDS, COPD,
necrotising lung parenchymal infection, influenza bronchiolitis,
Pneumocystis carnii pneumonia and even severe acute respiratory
syndrome (SARS)) [14]. Applying current understanding of the
disease to the existing knowledge it can be said that
SARS-CoV-2 virus might cause a similar degree of lung damage
making alveoli more susceptible to rupture.
This postulation of COVID-19, being a disease associated with
diffuse alveolar damage like SARS is further supported by the fact
that 8/10 of our patients had spontaneous pneumomediastinum
on their arrival CXR and the remaining two patients developed
it on second day of admission. The presence of spontaneous pul-
monary air leak on admission, before application of positive pres-
sure ventilation is signifying an alternative pathology other than
barotrauma for occurrence of this complication in COVID-19
ARDS patients.
Table 5. ARDS categorisation, treatment, assisted ventilation and clinical
outcomes
Patient (n = 10)
ARDS: n (%)
Moderate – (PaO2/FiO2 = 100–200) 2 (20%)









Non-invasive mechanical ventilation 7(70%)
Invasive mechanical ventilation 3 (30%)
Clinical outcomes:
Median duration of assisted ventilation before
pneumomediastinum (IQR) – days
5.5(1–9)
Median length of hospital 14 (8–25)
Length of ICU stay 8.6 (3–14)
Chest tube placement n (%) 5 (50%)
Mortality n (%) 7 (70%)
Discharged home n (%) 3 (30%)
Fig. 4. CT chest showing ground glass haziness with pulmonary cysts.
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Similar findings of spontaneous pneumomediastinum is also
reported in three other published case reports about COVID-19
patients [3, 15, 16].
One of our patient’s computed tomography of the chest
showed ground glass haziness and opacities in bilateral lungs
along with multiple randomly scattered pulmonary cysts of vari-
able sizes bilaterally, more marked in lower lung zones (Fig. 4).
A case report from Wuhan also described multiple bullae in
the computed tomography of the chest in a patient developing
SE [17]. These bullae could be an atypical presentation of
COVID-19 with tendency to rupture spontaneously. Lung condi-
tion like Pneumocystis carinii pneumonia are known to cause lung
cysts and pneumatocoele with tendency to spontaneously rupture
[18]. Coughing is a common symptom of COVID-19 and was also
present in eight out of 10 of our patients. Frequent bouts of cough
can be a critical factor contributing to this complication. It can be
presumed that NIV application during bouts of coughing might
have caused rapid increase in the peak inspiratory pressure
with resultant alveolar septal rupture. It is observed in past that
in the presence of peri-bronchial fibrosis, NIV application
particularly during coughing attack might increase traction on
small airways causing discontinuation of bronchoalveolar
junction [19].
Of note our results show that in all of our patients spontan-
eous pneumomediastinum occurred first and then SE developed
later over a period of 1–5 days. In five cases it progressed to
pneumothorax and in three cases air dissected even into lower
half of the body causing pneumoperitoneum (Fig. 6).
The outcomes were poor in majority of our cohort with 9 out
of 10 patients undergoing intubation and seven of them expired.
It seems like development of spontaneous pneumomediastinum
and SE which on their own are benign complications, are asso-
ciated with worse prognosis in COVID-19 patients. As the
recorded mortality in COVID-19 patients receiving mechanical
ventilation in our institute is around 25–30%, this signifies devel-
opment of spontaneous SE as a strong predictor of mortality in
Fig. 5. Chest x-ray showing SE (right image) and pneumothorax with chest tube on right side (left image).
Fig. 6. CT chest and abdomen showing extensive SE and pneumoperitoneum.
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these patients. Studies would be needed in future to look into
prognostic implications of these findings.
The two patients who survived in our case series had received
conservative treatment without any tube thoracostomy. Five
of our patients who developed worsening pneumomediastinum,
pneumothorax and haemodynamic compromise, underwent
chest tube thoracostomy. None of them survived.
Five of our patients received a combination therapy of steroids,
convalescent plasma and tocilizumab. Two of the survivors
received the combination treatment along with other ICU
management. As the sample size is small, and there are many
confounders which were not taken care of because of the descrip-
tive nature of the study, no inference about the treatment can be
drawn.
Retrospective collection of data is a major limitation of our
study due to which we might have missed some information
regarding clinical and ventilator parameters. The other limitations
were small sample size, actively evolving treatment protocols of a
new disease, observational case series from a single tertiary care
centre. Four patients had central line insertion before develop-
ment of SE but only one patient developed it on the next day.
Dissection from CVC insertion might have introduced external
air and have confounded the picture. One major limitation of
our study is the scoring system used to measure opacities based
on lung zone. Despite simplicity of use this CXR scoring system
is only experimental and would need further validation study to
be taken as standard. An additional limitation was the absence
of CT scan chest in majority of patients which would have clearly
defined the lesion and Macklin effect, if any.
However despite these limitations, this study adds to existing
knowledge about COVID-19 and would help in designing future
studies to look into this complication further.
Conclusion
Our findings suggest that it is lung damage secondary to inflamma-
tory response due to COVID-19 triggered by the use of positive
pressure ventilation which resulted in this complication. We
conclude that although development of spontaneous pneumome-
diastinum and SE are rare complications in critically ill
COVID-19 ARDS patients but are associated with worse prognosis.
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